Antiphospholipid antibodies are enriched post-acute COVID-19 but do not modulate the thrombotic risk
Clinical Immunology · 2023
DOI: 10.1016/j.clim.2023.109845 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2023. Verfasst von Marc Emmenegger und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland; Division of Medical Immunology, Department of Laboratory Medicine, Unive…. Hauptthemen laut MEDLINE: Influenza, Human, COVID-19, Antiphospholipid Syndrome, Thrombosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsspital Zürich, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Universität Zürich.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES: COVID-19-associated coagulopathy, shown to increase the risk for the occurrence of thromboses and microthromboses, displays phenotypic features of the antiphospholipid syndrome (APS), a prototype antibody-mediated autoimmune disease. Several groups have reported elevated levels of criteria and non-criteria antiphospholipid antibodies (aPL), assumed to cause APS, during acute or post-acute COVID-19. However, disease heterogeneity of COVID-19 is accompanied by heterogeneity in molecular signatures, including aberrant cytokine profiles and an increased occurrence of autoantibodies. Moreover, little is known about the association between autoantibodies and the clinical events. Here, we first aim to characterise the antiphospholipid antibody, anti-SARS-CoV-2 antibody, and the cytokine profiles in a diverse collective of COVID-19 patients (disease severity: asymptomatic to intensive care), using vaccinated individuals and influenza patients as comparisons. We then aim to assess whether the presence of aPL in COVID-19 is associated with an increased incidence of thrombotic events in COVID-19. METHODS AND RESULTS: We conducted anti-SARS-CoV-2 IgG and IgA microELISA and IgG, IgA, and IgM antiphospholipid line immunoassay (LIA) against 10 criteria and non-criteria antigens in 155 plasma samples of 124 individuals, and we measured 16 cytokines and chemokines in 112 plasma samples. We additionally employed clinical and demographic parameters to conduct multivariable regression analyses within multiple paradigms. In line with recent results, we find that IgM autoantibodies against annexin V (AnV), β2-glycoprotein I (β2GPI), and prothrombin (PT) are enriched upon infection with SARS-CoV-2. There was no evidence for seroconversion from IgM to IgG or IgA. PT, β2GPI, and AnV IgM as well as cardiolipin (CL) IgG antiphospholipid levels were significantly elevated in the COVID-19 but not in the influenza or control groups. They were associated predominantly with the strength of the anti-SARS-CoV-2 antibody titres and the major correlate for thromboses was SARS-CoV-2 disease severity. CONCLUSION: While we have recapitulated previous findings, we conclude that the presence of the aPL, most notably PT, β2GPI, AnV IgM, and CL IgG in COVID-19 are not associated with a higher incidence of thrombotic events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland; Division of Medical Immunology, Department of Laboratory Medicine, University Hospital Basel, 4031 Basel, Switzerland. Electronic address: mar…
- Department of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland.
- Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
- Institute of Intensive Care Medicine, University and University Hospital Zurich, Zurich, Switzerland.
- GA Generic Assays GmbH, Dahlewitz, Germany.
- GA Generic Assays GmbH, Dahlewitz, Germany; Institute of Biotechnology, Faculty Environment and Natural Sciences, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany; Faculty of Health Science…
Förderung
- Universitätsspital Zürich
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Universität Zürich
- Baugarten Stiftung
- NOMIS Stiftung
Zitieren
APA
Emmenegger, M., Emmenegger, V., Shambat, S. M., Scheier, T. C., Gomez-Mejia, A., Chang, C. C., Wendel-Garcia, P. D., Buehler, P. K., Buettner, T., Roggenbuck, D., Brugger, S. D., & Frauenknecht, K. B. M. (2023). Antiphospholipid antibodies are enriched post-acute COVID-19 but do not modulate the thrombotic risk. Clinical Immunology. https://doi.org/10.1016/j.clim.2023.109845
Vancouver
Emmenegger M, Emmenegger V, Shambat SM, Scheier TC, Gomez-Mejia A, Chang CC, et al. Antiphospholipid antibodies are enriched post-acute COVID-19 but do not modulate the thrombotic risk. Clinical Immunology. 2023. doi:10.1016/j.clim.2023.109845
BibTeX
@article{Emmenegger2023,
author = {Emmenegger, Marc and Emmenegger, Vishalini and Shambat, Srikanth Mairpady and Scheier, Thomas C and Gomez-Mejia, Alejandro and Chang, Chun-Chi and Wendel-Garcia, Pedro D and Buehler, Philipp K and Buettner, Thomas and Roggenbuck, Dirk and Brugger, Silvio D and Frauenknecht, Katrin B M},
title = {Antiphospholipid antibodies are enriched post-acute COVID-19 but do not modulate the thrombotic risk},
journal = {Clinical Immunology},
year = {2023},
doi = {10.1016/j.clim.2023.109845}
}
EUVIMED